The role of interferons in the treatment of osteosarcoma

Pediatr Blood Cancer. 2010 Mar;54(3):350-4. doi: 10.1002/pbc.22136.

Abstract

Interferons, a group of cytokines with antiangiogenic, direct antitumour and immunostimulating properties, have shown significant activity against osteosarcoma in vitro and in xenograft models. They have also been used in osteosarcoma clinical trials as a single adjuvant to surgery, with an apparent increase in relapse-free survival. In the ongoing EURAMOS 1 clinical trial, interferon alpha-2b is evaluated as an adjuvant treatment in osteosarcoma. This article reviews the rationale for the use of interferon in cancer with special reference to the treatment of osteosarcoma, including all published data of clinical efficacy in this disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / immunology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / immunology
  • Interferon-alpha / therapeutic use
  • Interferons / immunology
  • Interferons / therapeutic use*
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / immunology
  • Recombinant Proteins

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Interferons